Health Canada Authorizes Moderna’s mFLUSIVA and mCOFLU Vaccines

Nov 6, 2026 8:07 PM

View all comments（0）



Health Canada has authorized Moderna’s mRNA-based seasonal influenza vaccine, mFLUSIVA, and its combined influenza and COVID-19 vaccine, mCOFLU, for adults aged 50 and older. This makes Canada the first nation globally to approve both vaccines. Moderna plans to collaborate with Canadian health authorities and immunization partners to facilitate the future availability of these products in the country, marking a significant milestone in commercializing its mRNA vaccine portfolio and potentially boosting future immunization rates and market positioning.

AI-generated summary

Health Canada has authorized Moderna, Inc.’s mFLUSIVA® (Influenza mRNA vaccine; mRNA-1010) and mCOFLU® (Combined Influenza and COVID-19 mRNA vaccine; mRNA-1083) for adults aged 50 and older.

Canada is the first country in the world to authorize both Moderna’s seasonal mRNA influenza vaccine and its combined influenza and COVID-19 vaccine.

Moderna said it will engage with Canadian health authorities and immunization partners as it advances plans for the future availability of mFLUSIVA and mCOFLU in Canada.

This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Tesla Rises Nearly 3% Premarket as Musk Says Texas Plant to Phase Out Cybertruck Production by Mid-2027 to Make Way for Cybercab Expansion

TradingKey - On November 6, Eastern Time, Tesla (TSLA) shares rose 2.8% in pre-market trading to $353.3. In the previous trading session, Tesla shares fell 10.77% to close at $343.69.

SpaceX Falls Over 9%, Down Nearly 30% From October High; Musk Reposts Investor Analysis on Texas Proposed Pause on New Data Center Approvals

TradingKey - On November 5, Eastern Time, SpaceX (SPCX) shares fell 9.05% to close at $123.62, marking a second consecutive trading day of declines and retreating about 29.9% from its October intraday high of $176.42.

Today’s Market Recap: Nasdaq Falls Over 5%, AI Stocks Plunge as Nvidia Drops Over 9%, Micron Falls Over 17%, SanDisk Drops Over 22%

TradingKey - In the Asian session on November 6, the three major U.S. stock indices tumbled across the board overnight, with selling intensifying across the AI data center supply chain and largely erasing the previous session's rebound. As market concerns mounted over AI infrastructure financing cos

Kospi Plunges 8% to Trigger Level 1 Circuit Breaker and Fall Below 5,000, Nikkei Sinks 6% as SK Hynix and Samsung Tumble Over 10%

The KOSPI plunged 8.55%, triggering a Level 1 circuit breaker and crashing below 5,000 points, as SK Hynix tumbled 12% and Samsung plummeted 10%.

Nasdaq Drops Over 5%, Philadelphia Semiconductor Index Plunges 12% as Chip and AI Infrastructure Stocks Are Sold Off; Micron Falls 17%, Nvidia Drops 9%

On Thursday, November 5, Eastern Time, U.S. stocks tumbled sharply, giving back gains from the previous session's post-election rally. Mounting market concerns over a slowdown in data center construction prompted investors to accelerate their offloading of tech shares, with chipmakers and AI infrastructure-related stocks bearing the brunt of the sell-off. At the close, the Dow Jones Industrial Average dropped 3.44% to 51,523.06; the Nasdaq Composite Index tumbled 5.52% to 24,315.00; and the S&P 500 Index fell 4.36% to 7,353.73, marking its largest single-day decline since April 2025.

Featured Tools